Small molecule · Inhibitor of programmed death-ligand 1 (CD274) · developed by Incyte
INCB099280 is an orally bioavailable small molecule that binds PD-L1 expressed on tumor cells, blocking its interaction with PD-1 and reversing T-cell inactivation. It is being studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05888844 | Phase 2 | Cutaneous Squamous Cell Carcinoma | Terminated | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
Updated Nov 15, 2026. Something wrong or missing? Report it on the INCY page.
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →